Inceptor Bio Takes a Major Step in Clinical Trials for Cancer Therapy with New Funding

Inceptor Bio Initiates First Patient Dosing for IB-T101 Clinical Trials

On February 25, 2025, Inceptor Bio, a clinical-stage biotechnology firm specializing in cutting-edge cell therapies, marked a significant milestone by administering the first dose of their lead program, IB-T101, to a patient. This pivotal moment in cancer treatment focuses on clear cell Renal Cell Carcinoma (ccRCC), addressing a critical gap in medical needs for patients suffering from this prevalent form of kidney cancer.

The Innovative IB-T101 Therapy

IB-T101 is a novel autologous CAR-T therapy specifically designed to target CD70, a tumor-associated antigen that is notably overexpressed in clear cell RCC and several other cancers. The innovative therapy is based on Inceptor Bio's proprietary OUTLAST™ platform, which aims to metabolically reprogram T cells. This unique approach conditions the T cells to survive and thrive within the challenging tumor microenvironment (TME).

Clinical Trial Details

The current clinical trial, identified as an Investigator-Initiated Trial (IIT), is focused on evaluating the safety, tolerability, and preliminary effectiveness of IB-T101 for patients who have had relapses after receiving prior VEGF-targeting therapies, both alone and in conjunction with immune checkpoint inhibitors. With the inclusion of a dose-escalation phase, the trial aims to identify the optimal dosage for this promising therapy.

The primary endpoints of this clinical study will include the assessment of safety and tolerability, while secondary endpoints will examine both pharmacokinetics and anti-tumor activity.

Funding to Support Development

In conjunction with this milestone, Inceptor Bio successfully closed a Series A2 financing round, securing $21 million. This financing will facilitate ongoing clinical development for IB-T101 and fund the expansion of their next-generation cell therapy pipeline. The financing round was led by trusted insiders including Kineticos Life Sciences, a significant endorsement of Inceptor's innovative approach to cancer therapies.

Dr. Matthias Schroff, the CEO of Inceptor Bio, expressed enthusiasm about this advancement, stating, "This is a major milestone for Inceptor Bio as we advance IB-T101 into the clinic. Just like elite athletes who train in high-elevation environments develop attributes to excel, we believe that our T cells, conditioned through our unique platform, will significantly outperform in treating solid tumors. Our investors’ unwavering support empowers us to focus on delivering what we hope will be a best-in-class therapy for patients facing challenging cancers."

A Commitment to Making a Difference

Shailesh Maingi, Managing Partner at Kineticos Life Sciences, emphasized the importance of this achievement for Inceptor, affirming, "Dosing the first patient in a clinical trial is a significant milestone for any biotech company. We are proud to support Inceptor Bio as they bring IB-T101 forward in clinical settings. The OUTLAST™ platform offers a robust approach to overcoming obstacles in CAR-T therapy, with the potential to positively impact the lives of patients battling solid tumors."

About Clear Cell Renal Cell Carcinoma

Clear cell RCC statistics reveal that it stands as the most prevalent kidney cancer type, with more than 300,000 new cases diagnosed globally each year. Unfortunately, the limited treatment options available for this condition highlight the urgent need for effective therapies. This amplifies the significance of Inceptor Bio's efforts with IB-T101 in advancing treatment options for those affected by ccRCC.

About Inceptor Bio

Founded in May 2020 and based in Research Triangle Park, North Carolina, Inceptor Bio is committed to revolutionizing cancer treatment through next-generation cell and gene therapies. With a strong pipeline and an impressive leadership team, the organization is dedicated to developing innovative therapies that improve patient outcomes for individuals facing limited treatment options worldwide. For more information about their initiatives and upcoming therapies, please visit Inceptor Bio.

As healthcare continues to evolve with groundbreaking therapies like IB-T101, the future for patients diagnosed with clear cell RCC holds promise for improved outcomes and innovative treatment strategies.